Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Pediatric Endocrinology

Can Premature Babies Have a False-Positive CAH Screen?

At a Glance

A positive CAH newborn screen does not confirm congenital adrenal hyperplasia in a premature baby. Immature adrenal glands and illness can raise the screening hormone 17-OHP, but prompt follow-up remains essential because true CAH can cause a dangerous adrenal crisis.

Receiving a call about an abnormal newborn screen while your baby is in the Neonatal Intensive Care Unit (NICU) is frightening. If your premature baby has a positive screen for Congenital Adrenal Hyperplasia (CAH), it is important to know that a screening result is not a diagnosis.

In premature, low-birth-weight, or critically ill infants, this test frequently flags a positive result even when the baby does not have CAH (a false-positive screen) [1][2]. However, because true classic CAH can cause a life-threatening adrenal crisis in the first weeks of life, a positive screen is never ignored and always requires prompt evaluation by your care team [3].

What This Result Means Right Now

  • A positive screen simply means more testing is needed to find out if your baby actually has CAH or if the result was temporarily influenced by their prematurity.
  • Follow your NICU team’s urgent follow-up plan. Do not wait for a repeat screen if the team advises immediate diagnostic testing.
  • Warning Signs: Even if a false positive is strongly suspected, tell your medical team immediately if your baby experiences poor feeding, repeated vomiting, unusual sleepiness, weakness, dehydration (fewer wet diapers), or worsening illness [3]. Some babies show no early signs, so never wait for symptoms to complete the follow-up testing.

Why do false-positive screens happen in premature babies?

The standard newborn screen for CAH measures a hormone building block called 17-OHP (17-hydroxyprogesterone) [4]. In true CAH, a genetic enzyme deficiency prevents the adrenal glands from making essential hormones like cortisol (which helps the body respond to stress) and sometimes aldosterone (which balances salt and water). As a result, the 17-OHP building block backs up and reaches very high levels.

However, premature babies often have elevated 17-OHP for reasons entirely unrelated to CAH:

  • Immature Adrenal Glands: A premature baby’s adrenal glands (small organs sitting on top of the kidneys that produce essential hormones) are still developing. Their early steroid hormone profiles naturally look different from those of full-term babies, leading to higher baseline levels of 17-OHP [4][5]. In babies without CAH, these levels generally decrease as they mature [4].
  • Physical Stress: Illnesses, breathing difficulties, or the physical stress of an early delivery can cause a tiny baby’s body to temporarily spike 17-OHP levels [6][7].
  • Test Limitations: The initial screening test (called an immunoassay) aims to maximize sensitivity to catch as many true cases of CAH as possible [8]. However, its testing chemicals can cross-react with normal physiological steroid precursors that are naturally abundant in premature babies [9]. This makes the measured 17-OHP level look artificially higher than it actually is.

Because 17-OHP naturally increases as gestational age and birth weight decrease, standard screening cutoffs will often flag perfectly healthy premature babies [1][2].

How do doctors clarify the result?

When a screen is positive, the next steps depend on the specific 17-OHP value, your baby’s gestational age, their birth weight, and their clinical health [10][11]. The care team, often alongside a pediatric endocrinologist (a hormone specialist), will determine the safest follow-up plan:

  • Urgent Blood Tests and Monitoring: If the screening levels are markedly high or the baby is unwell, doctors will immediately draw blood from a vein to measure hormones accurately. They will also closely monitor electrolytes (sodium and potassium), glucose, and hydration to check for signs of a dangerous salt-wasting crisis [12][11].
  • Second-Tier Testing (LC-MS/MS): Some screening programs automatically run an advanced follow-up test on the original blood spot called LC-MS/MS (liquid chromatography-tandem mass spectrometry) [8]. This test is more specific: it measures 17-OHP alongside other steroids (like 21-deoxycortisol) to help distinguish between a stressed premature adrenal gland and true CAH, sharply reducing the number of false-positive alarms [13]. However, this specialized test is not available everywhere and its results still require careful clinical interpretation.
  • Repeat Newborn Screening: For certain low-risk or borderline results, the protocol may require a repeat heel-prick screen a few days or weeks later, depending on local guidelines [10][14].

If true CAH is confirmed, highly effective daily hormone replacement medications are available. Your medical team will teach you exactly how to manage the condition and keep your baby safe during illnesses [15].

Common questions in this guide

Does a positive CAH screen mean my premature baby has CAH?
No. A positive newborn screen only means that more testing is needed, and prematurity, low birth weight, or illness can raise 17-OHP without CAH. Follow-up is still important because classic CAH can cause a life-threatening adrenal crisis.
Why can a premature baby's 17-OHP level be high?
Premature babies have developing adrenal glands, and early delivery, breathing problems, or other illness can temporarily increase 17-OHP. The first screening test can also react with related hormone building blocks that are common in premature infants. Levels often fall as the baby matures, but the result must be checked by the care team.
What tests are done after an abnormal CAH newborn screen?
Depending on the result and the baby's health, clinicians may order blood tests for hormones and monitor sodium, potassium, glucose, and hydration. Some programs use a more specific test called LC-MS/MS, while borderline results may lead to a repeat heel-prick screen. A pediatric endocrinologist may help interpret the results.
What warning signs could mean a baby is developing an adrenal crisis?
Seek immediate medical help for poor feeding, repeated vomiting, unusual sleepiness, weakness, fewer wet diapers or other signs of dehydration, or worsening illness. Some babies may have few early symptoms, so do not wait for warning signs before completing recommended follow-up testing.
How soon should a premature baby's positive CAH screen be followed up?
Follow the NICU team's plan promptly rather than waiting for symptoms. Markedly high screening results or an unwell baby may require immediate diagnostic blood tests and monitoring, while a borderline or lower-risk result may be handled with a repeat screen under local guidelines.
What treatment is available if my baby's CAH is confirmed?
CAH can be treated with daily hormone replacement medicines. The medical team will explain dosing, follow-up, and how to manage the condition during illness to help keep the baby safe.

Get notified when new evidence is published on Congenital adrenal hyperplasia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    Establishing 17-Hydroxyprogesterone Cutoff Values for Congenital Adrenal Hyperplasia in Preterm, Low Birth Weight, and Sick Newborns.

    Yoon YA, Woo S, Kim MS, et al.

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2023; (131(4)):216-221 doi:10.1055/a-2022-8399.

    PMID: 36854385
  2. 2

    Combined Gestational Age- and Birth Weight-Adjusted Cutoffs for Newborn Screening of Congenital Adrenal Hyperplasia.

    Pode-Shakked N, Blau A, Pode-Shakked B, et al.

    The Journal of clinical endocrinology and metabolism 2019; (104(8)):3172-3180 doi:10.1210/jc.2018-02468.

    PMID: 30865229
  3. 3

    Thirty-Year Lessons from the Newborn Screening for Congenital Adrenal Hyperplasia (CAH) in Japan.

    Tsuji-Hosokawa A, Kashimada K

    International journal of neonatal screening 2021; (7(3)) doi:10.3390/ijns7030036.

    PMID: 34209888
  4. 4

    Elevation of corticosterone and 17OH progesterone in extremely preterm infants and clinical implications.

    Kessel JM, Held PK, Bialk ER, et al.

    Pediatric research 2026; (99(3)):1085-1095 doi:10.1038/s41390-025-04216-5.

    PMID: 40775060
  5. 5

    17-hydroxiprogesterone values in healthy preterm infants.

    Mendoza-Rojas VC, Díaz-Martínez LA, Mantilla-Mora G, et al.

    Colombia medica (Cali, Colombia) 2017; (48(4)):161-166 doi:10.25100/cm.v43i4.2983.

    PMID: 29662257
  6. 6

    Evaluation of factors associated with elevated newborn 17-hydroxyprogesterone levels.

    Anandi VS, Shaila B

    Journal of pediatric endocrinology & metabolism : JPEM 2017; (30(6)):677-681.

    PMID: 28489558
  7. 7

    Congenital Adrenal Hyperplasia: Time to Replace 17OHP with 21-Deoxycortisol.

    Miller WL

    Hormone research in paediatrics 2019; (91(6)):416-420 doi:10.1159/000501396.

    PMID: 31450227
  8. 8

    Wisconsin's Screening Algorithm for the Identification of Newborns with Congenital Adrenal Hyperplasia.

    Bialk ER, Lasarev MR, Held PK

    International journal of neonatal screening 2019; (5(3)):33 doi:10.3390/ijns5030033.

    PMID: 33072992
  9. 9

    Generation of monoclonal antibodies against 17α-hydroxyprogesterone for newborn screening of congenital adrenal hyperplasia.

    Morejón García G, García de la Rosa I, González Reyes EC, et al.

    Clinica chimica acta; international journal of clinical chemistry 2018; (485()):311-315 doi:10.1016/j.cca.2018.07.019.

    PMID: 30006291
  10. 10

    Neonatal 17-hydroxyprogesterone levels adjusted according to age at sample collection and birthweight improve the efficacy of congenital adrenal hyperplasia newborn screening.

    Hayashi GY, Carvalho DF, de Miranda MC, et al.

    Clinical endocrinology 2017; (86(4)):480-487 doi:10.1111/cen.13292.

    PMID: 27978607
  11. 11

    Four Consecutive False Negative Newborn Screens in a Patient with Classical Congenital Adrenal Hyperplasia: A Case Report

    Rizzuto P, Gangat M, Khattab A, Marshall I

    Journal of clinical research in pediatric endocrinology 2026; (18(Suppl 1)):92-96 doi:10.4274/jcrpe.galenos.2025.2024-10-16.

    PMID: 41797552
  12. 12

    Efficacy of Liquid-chromatography and Radioimmunoassay in False-positives' Drop-off in CAH Newborn Screening.

    Carvalho DF, Lima-Valassi HP, Hayashi GY, et al.

    The Journal of clinical endocrinology and metabolism 2026; (111(8)):2210-2219 doi:10.1210/clinem/dgag107.

    PMID: 41811754
  13. 13

    Second-tier Testing for 21-Hydroxylase Deficiency in the Netherlands: A Newborn Screening Pilot Study.

    Stroek K, Ruiter A, van der Linde A, et al.

    The Journal of clinical endocrinology and metabolism 2021; (106(11)):e4487-e4496 doi:10.1210/clinem/dgab464.

    PMID: 34171085
  14. 14

    Outcome of Newborn Screening for Congenital Adrenal Hyperplasia at Two Time Points.

    Eshragh N, Doan LV, Connelly KJ, et al.

    Hormone research in paediatrics 2020; (93(2)):128-136 doi:10.1159/000508075.

    PMID: 32659761
  15. 15

    Evaluation of a Two-Tier Screening Pathway for Congenital Adrenal Hyperplasia in the New South Wales Newborn Screening Programme.

    Lai F, Srinivasan S, Wiley V

    International journal of neonatal screening 2020; (6(3)):63 doi:10.3390/ijns6030063.

    PMID: 33117905

This information about false-positive CAH screening is for educational purposes only and does not constitute medical advice. Your NICU team and pediatric endocrinologist should interpret your baby's results and guide urgent follow-up.